| IMMATICS N.V. |
| Niederlande |
| Gesundheit |
| NL0015285941 / A2P72S |
| 4A3 (Frankfurt) |
| FRA:4A3, ETR:4A3, 4A3:GR |
| - |
| https://immatics.com/ |
|
Immatics N.V. is a biotechnology company dedicated to the discovery and development of T-cell redirecting cancer immunotherapies. The company's primary function is to harness the power of the body's immune system to target and eliminate cancer cells,..
>Volltext.. |
| 1323.85 Mio. EUR |
| 886.86 Mio. EUR |
| 37.17 Mio. EUR |
| -204.29 Mio. EUR |
| -212.71 Mio. EUR |
| -1.69 EUR |
| 14.9 Mio. EUR |
| 297.8 Mio. EUR |
| - |
| 8.21 |
| -73.87% |
| -913.68% |
| - |
| - |
| - |
| - |
| IMMATICS |
| 01.06.26 |
|